3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium

The IRS raised 2026 HSA contribution limits to $4,400 for individuals and $8,750 for families (age‑55 catch‑up remains $1,000) while Medicare Part B premiums increase to $202.90/month and the Part B deductible to $283, tightening seniors' budgets. These policy shifts enhance HSA attractiveness for durable medical equipment and increase demand pressure for cost‑reducing or remote‑monitoring medical devices, benefiting firms like DexCom, ResMed and Masimo. Zacks assigns each company a Rank #3; DexCom's 2026 earnings estimates fell 3.5% in 60 days but still imply 19.6% growth over 2025, while ResMed's estimates rose 1.1% (implying +9.2%) and Masimo's rose 1.2% (implying +6.3%), supporting a modestly constructive investment case tied to demographic and reimbursement dynamics.

Analysis

Market structure: The modest HSA bump ($100 individual/$200 family) and a $18 rise in Medicare Part B premiums (to $202.90/mo) nudge consumers toward tax-advantaged spending and cost-avoiding technologies, favoring incumbents with reimbursable, higher-ticket devices — namely DXCM (CGM), RMD (PAP/connected care) and MASI (remote monitoring). Pricing power accrues to market leaders who can bundle sensors, subscriptions and services; smaller low-cost vendors face margin pressure as payers push for outcomes-driven products. Cross-asset: Expect modest defensive bid for healthcare equities vs cyclical consumer names; slight downward pressure on consumer discretionary and municipal bonds in states with large retiree bases if out-of-pocket burdens rise.

Risk assessment: Tail risks include CMS reimbursement reversals, a major device recall, or a rapid secular decline in insulin-dependent patient volumes due to GLP-1 adoption (could reduce CGM usage by >10% over 2–3 years). Immediate (days) risks center on earnings/guide; short-term (3–12 months) on CMS rule-making and coding updates; long-term (2–5 years) on demographic shifts and therapeutic displacement. Hidden dependencies: HSA utilization rates (historically ~20–30% of eligible balances are used annually) and provider prescribing patterns; both will determine real uptake, not just dollar limits. Catalysts: CMS coverage expansions, major payer pilots for remote monitoring, or quarterly beats can accelerate adoption.

Trade implications: Tactical overweight DXCM (highest sensitivity to HSA/Medicare tailwinds) with layered entries over 30–90 days; use 9–15 month call spreads to limit capital. Buy RMD for stable recurring revenue and digital services exposure (target 9–12 month hold). Keep MASI as a smaller, hedged exposure given litigation/coverage noise — prefer collars or cash-secured puts rather than naked long.

Contrarian angles: The market understates GLP-1 therapy risk to CGM demand and overstates the impact of a modest HSA bump; real-dollar change is small relative to device lifecycle costs. Coverage/coding changes (NCD/LCD) could swing adoption fast — a negative CMS memo would hurt DXCM materially. Historical parallel: reimbursements-driven adoption in dialysis and CPAP shows uptake only after definitive CMS decisions; treat current optimism as contingent, not guaranteed.

Key Decisions for Investors

• Establish a 1–2% long position in DXCM over 30–90 days, scaling in 3 tranches; hedge with a 12–15 month call spread (buy 1x longer-dated call, sell higher strike) to cap downside; target a 18–25% return in 12 months and set a hard sell/stop at -15%.
• Allocate 1–1.5% to RMD with a 9–12 month horizon—prefer 9–12 month call spreads or outright shares with a 10% stop—expect 8–12% upside as recurring revenue and improved estimates play out; add if quarterly results beat revenue growth by >150 bps vs consensus.
• Keep MASI exposure to 0.5–1% and use downside protection: buy 6–9 month puts or execute collars; consider selling short-dated covered calls to harvest premium if holding. Trim if adverse CMS or legal headlines widen implied volatility by >40% from current levels.
• Implement a pair trade: long DXCM (1.0%) vs short MASI (0.75%) over 6–12 months to express higher conviction in CGM reimbursement sensitivity; unwind if DXCM underperforms MASI by >10% in 60 days or if CMS issues favorable broad monitoring coverage for Masimo products.
• Monitor three specific catalysts in the next 60 days before adding: (1) any CMS NCD/LCD announcements on CGM/PAP/remote monitoring, (2) quarterly revenue/sensor-subscription trends vs consensus, and (3) GLP-1 adoption metrics (monthly script growth >5% m/m) that could reduce insulin-dependent populations.